{"id":45341,"date":"2022-06-22T09:01:45","date_gmt":"2022-06-22T07:01:45","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/battery-ventures-makes-majority-investment-in-titian-software\/"},"modified":"2022-06-22T09:01:45","modified_gmt":"2022-06-22T07:01:45","slug":"battery-ventures-makes-majority-investment-in-titian-software","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/battery-ventures-makes-majority-investment-in-titian-software\/","title":{"rendered":"Battery Ventures Makes Majority Investment in Titian Software"},"content":{"rendered":"
\n

\nDeal will fuel continued growth at U.K.-based, sample-management software company, which improves research processes for critical biotech, pharmaceutical and academic organizations<\/i>\n<\/p>\n

BOSTON–(BUSINESS WIRE)–#industrialtech<\/a>–Battery Ventures, a global, technology-focused investment firm, announced a significant, majority investment in Titian Software Ltd., a U.K. company that develops innovative sample-management software and related services for life-sciences laboratories. Specific terms were not disclosed.\n<\/p>\n

<\/a><\/p>\n

\nTitian, based in London, makes technology for the entire sample-management process, helping customers maximize the efficiency of their research and development. More specifically, the company\u2019s Mosaic product improves the supply of samples\u2014including compounds, biologicals and reagents\u2014essential to vital research and development processes in the lab. The company sells into industries including pharmaceuticals and biopharmaceuticals; agro science; contract research organizations; and not-for-profit and academic groups.\n<\/p>\n

\nTitian will use the new funds to support organic growth as well as potential future acquisitions, said Battery General Partner Jesse Feldman.\n<\/p>\n

\n\u201cThe broader life-sciences sample-management market is poised for more growth, with trends such as personalized medicine and genomic sequencing driving more high-throughput, lab screening, as well as the creation of new labs to support this activity. All of this will drive growth at Titian,\u201d Feldman said. Battery has extensive experience in the market, including through previous investments in another sample-management\/sample-preparation company and in a laboratory-software company.\n<\/p>\n

\nTitian\u2019s founder, Edmund Wilson, retains a meaningful ownership stake in the company and will remain closely involved in leading the business going forward.\n<\/p>\n

\n\u201cTitian has been on a solid growth trajectory of late,\u201d Wilson said. \u201cBut our new partnership with Battery represents a key inflection point for the company that should allow us to scale even further, in part by tapping Battery\u2019s industry expertise, network and market savvy. With Battery\u2019s help, Titian can better capitalize on the exciting growth opportunities we see ahead in the sample-management sector.\u201d\n<\/p>\n

\nTitian\u2019s Mosaic helps researchers better manage and automate critical processes, allowing its customers to maximize research efficiency and speed up the discovery and delivery of new drugs.\n<\/p>\n

\n\u201cTitian\u2019s products are particularly critical to many organizations right now, as increased lab automation can help organizations counteract labor shortages in the current market,\u201d said Battery\u2019s Justin Rosner, who will join Titian\u2019s board along with Jesse Feldman. \u201cMore broadly, lab automation helps Titian\u2019s customers perform critical testing activities more quickly, accurately and efficiently.\u201d\n<\/p>\n

\n*For a full list of all Battery investments and exits, click <\/i>here<\/i><\/a>.<\/i>\n<\/p>\n

\nAbout Titian<\/b>\n<\/p>\n

\nTitian Software was founded in 1999 and specialises in sample management. It offers software products and consultancy services that help clients improve the supply of samples (compounds, biologicals and reagents) to their vital research processes. Using the company\u2019s Mosaic software, Titian\u2019s customers see significant benefits in terms of throughput, response times, error rates, labour costs and sample conservation performance of their sample banks. We use our experience of integrating laboratory robotics into our systems to ensure that our clients make best use of their investment in automation.\n<\/p>\n

\nAbout Battery Ventures<\/b>\n<\/p>\n

\nBattery partners with exceptional founders and management teams developing category-defining businesses in markets including software and services, enterprise infrastructure, online marketplaces, healthcare IT and industrial technology. Founded in 1983, the firm backs companies at all stages, ranging from seed and early to growth and buyout, and invests globally from six strategic locations: Boston; San Francisco and Menlo Park, Calif.; Tel Aviv; London; and New York. Follow the firm on Twitter @BatteryVentures, visit our website at www.battery.com<\/a> and find a full list of Battery\u2019s portfolio companies here.<\/a>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nRebecca Buckman
\n
becky@battery.com<\/a>
650-292-2077\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Deal will fuel continued growth at U.K.-based, sample-management software company, which improves research processes for critical biotech, pharmaceutical and academic organizations BOSTON–(BUSINESS WIRE)–#industrialtech–Battery Ventures, a global, technology-focused investment firm, announced a significant, majority investment in Titian Software Ltd., a U.K. company that develops innovative sample-management software and related services for life-sciences laboratories. Specific terms were … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-45341","6":"format-standard","7":"category-industry"},"yoast_head":"\nBattery Ventures Makes Majority Investment in Titian Software - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/battery-ventures-makes-majority-investment-in-titian-software\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Battery Ventures Makes Majority Investment in Titian Software - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Deal will fuel continued growth at U.K.-based, sample-management software company, which improves research processes for critical biotech, pharmaceutical and academic organizations BOSTON–(BUSINESS WIRE)–#industrialtech–Battery Ventures, a global, technology-focused investment firm, announced a significant, majority investment in Titian Software Ltd., a U.K. company that develops innovative sample-management software and related services for life-sciences laboratories. Specific terms were ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/battery-ventures-makes-majority-investment-in-titian-software\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-22T07:01:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220622005298\/en\/718172\/21\/NewBatteryLogo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/battery-ventures-makes-majority-investment-in-titian-software\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/battery-ventures-makes-majority-investment-in-titian-software\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Battery Ventures Makes Majority Investment in Titian Software\",\"datePublished\":\"2022-06-22T07:01:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/battery-ventures-makes-majority-investment-in-titian-software\\\/\"},\"wordCount\":603,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/battery-ventures-makes-majority-investment-in-titian-software\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220622005298\\\/en\\\/718172\\\/21\\\/NewBatteryLogo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/battery-ventures-makes-majority-investment-in-titian-software\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/battery-ventures-makes-majority-investment-in-titian-software\\\/\",\"name\":\"Battery Ventures Makes Majority Investment in Titian Software - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/battery-ventures-makes-majority-investment-in-titian-software\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/battery-ventures-makes-majority-investment-in-titian-software\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220622005298\\\/en\\\/718172\\\/21\\\/NewBatteryLogo.jpg\",\"datePublished\":\"2022-06-22T07:01:45+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/battery-ventures-makes-majority-investment-in-titian-software\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/battery-ventures-makes-majority-investment-in-titian-software\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/battery-ventures-makes-majority-investment-in-titian-software\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220622005298\\\/en\\\/718172\\\/21\\\/NewBatteryLogo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220622005298\\\/en\\\/718172\\\/21\\\/NewBatteryLogo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/battery-ventures-makes-majority-investment-in-titian-software\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Battery Ventures Makes Majority Investment in Titian Software\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Battery Ventures Makes Majority Investment in Titian Software - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/battery-ventures-makes-majority-investment-in-titian-software\/","og_locale":"en_US","og_type":"article","og_title":"Battery Ventures Makes Majority Investment in Titian Software - Pharma Trend","og_description":"Deal will fuel continued growth at U.K.-based, sample-management software company, which improves research processes for critical biotech, pharmaceutical and academic organizations BOSTON–(BUSINESS WIRE)–#industrialtech–Battery Ventures, a global, technology-focused investment firm, announced a significant, majority investment in Titian Software Ltd., a U.K. company that develops innovative sample-management software and related services for life-sciences laboratories. Specific terms were ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/battery-ventures-makes-majority-investment-in-titian-software\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-22T07:01:45+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220622005298\/en\/718172\/21\/NewBatteryLogo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/battery-ventures-makes-majority-investment-in-titian-software\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/battery-ventures-makes-majority-investment-in-titian-software\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Battery Ventures Makes Majority Investment in Titian Software","datePublished":"2022-06-22T07:01:45+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/battery-ventures-makes-majority-investment-in-titian-software\/"},"wordCount":603,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/battery-ventures-makes-majority-investment-in-titian-software\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220622005298\/en\/718172\/21\/NewBatteryLogo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/battery-ventures-makes-majority-investment-in-titian-software\/","url":"https:\/\/pharma-trend.com\/en\/battery-ventures-makes-majority-investment-in-titian-software\/","name":"Battery Ventures Makes Majority Investment in Titian Software - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/battery-ventures-makes-majority-investment-in-titian-software\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/battery-ventures-makes-majority-investment-in-titian-software\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220622005298\/en\/718172\/21\/NewBatteryLogo.jpg","datePublished":"2022-06-22T07:01:45+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/battery-ventures-makes-majority-investment-in-titian-software\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/battery-ventures-makes-majority-investment-in-titian-software\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/battery-ventures-makes-majority-investment-in-titian-software\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220622005298\/en\/718172\/21\/NewBatteryLogo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220622005298\/en\/718172\/21\/NewBatteryLogo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/battery-ventures-makes-majority-investment-in-titian-software\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Battery Ventures Makes Majority Investment in Titian Software"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45341","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=45341"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45341\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=45341"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=45341"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=45341"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}